relugolix
relugolix: sourced relationships with 1 company · 14 clinical trials tracked.
relugolix evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
How could relugolix → MYOV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Myovant Sciences Ltd. (MYOV) advanced prostate cancer | Approved |
Clinical Trial Registry Records (14)showing 10 most recent
Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: The REVELUTION-2 Trial
Primary endpoint: Incidence of ambulatory systolic blood pressure (BP) > 140 or diastolic > 90 (measurement on 2 separate days)
Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)
Primary endpoint: Proportion of patient experiencing dose limiting toxicity (DLT) and tolerable dose of relugolix and enzalutamide combination
Comeback From Long coursE ADT With RElugolix and Darolutamide in Hormone-sensitive Prostate Cancer (CLEARED)
Primary endpoint: 18-month Rate of Testosterone Recovery
Optimizing Treatment and Advanced Multi-Imaging Response Evaluation for Very-High-Risk Prostate Cancer (OPTIMAL) - a Phase II Single Arm Study
Primary endpoint: Pathologic response (biopsy positivity rate)
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
Primary endpoint: This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone.
A Comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on Cardiovascular Function and Biomarkers During Standard of Care Combined ADT (Androgen Deprivation Therapy)-Radiation for Prostate Cancer
Primary endpoint: Physiologic alterations in cardiopulmonary function - Myocardial perfusion
MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)
RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer
Primary endpoint: 9-month Quality of Life (QOL) Score
Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial.
Primary endpoint: Fibroid recurrence on ultrasound after myomectomy.
Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix
Primary endpoint: Total Coronary Plaque Volume in Major Coronary Arteries (i.e. Left Anterior Descending, Left Circumflex, Right Major Coronary Arteries)
Frequently asked questions
Which companies have sourced relationships with relugolix?
relugolix has dated SEC/FDA relationship records for Myovant Sciences Ltd..
How many clinical trials involve relugolix?
BioSniper tracks 14 clinical trials involving relugolix.